Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Analysts at Cantor Fitzgerald decreased their FY2017 earnings estimates for shares of Aldeyra Therapeutics in a research note issued on Sunday. Cantor Fitzgerald analyst E. Piros now forecasts that the biotechnology company will post earnings per share of ($1.34) for the year, down from their prior forecast of ($1.30). Cantor Fitzgerald currently has a “Overweight” rating and a $22.00 target price on the stock.
Aldeyra Therapeutics (NASDAQ:ALDX) last announced its earnings results on Thursday, November 9th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.09.
TRADEMARK VIOLATION WARNING: “Cantor Fitzgerald Equities Analysts Decrease Earnings Estimates for Aldeyra Therapeutics, Inc. (ALDX)” was first reported by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.themarketsdaily.com/2017/11/16/cantor-fitzgerald-equities-analysts-decrease-earnings-estimates-for-aldeyra-therapeutics-inc-aldx.html.
Shares of Aldeyra Therapeutics (NASDAQ ALDX) opened at $6.20 on Wednesday. Aldeyra Therapeutics has a 52 week low of $3.80 and a 52 week high of $11.90. The company has a debt-to-equity ratio of 0.02, a current ratio of 20.35 and a quick ratio of 20.35.
In related news, major shareholder Life Sciences Maste Perceptive bought 200,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 19th. The shares were purchased at an average cost of $7.25 per share, with a total value of $1,450,000.00. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 28.40% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in shares of Aldeyra Therapeutics by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock valued at $1,431,000 after buying an additional 9,407 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in Aldeyra Therapeutics during the 3rd quarter worth $134,000. Virtu KCG Holdings LLC acquired a new stake in Aldeyra Therapeutics during the 2nd quarter worth $104,000. Renaissance Technologies LLC acquired a new stake in Aldeyra Therapeutics during the 1st quarter worth $132,000. Finally, Hikari Power Ltd boosted its stake in Aldeyra Therapeutics by 186.4% during the 2nd quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock worth $507,000 after purchasing an additional 70,196 shares during the period. 40.34% of the stock is currently owned by hedge funds and other institutional investors.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.